Страна: Нова Зеландия
Език: английски
Източник: Medsafe (Medicines Safety Authority)
Influenza virus A/California/7/2009 (H1N1) - like strain 9ug (A/California/7/2009 NYMC X-179A); Influenza virus A/Texas/50/2012 (H3N2) like strain 9ug (A/Texas/50/2012 NYMC X-223A); Influenza virus B/Massachusetts/2/2012 like strain 9ug (wild type)
sanofi-aventis new zealand limited
Influenza virus A/California/7/2009 (H1N1) - like strain 9 µg (A/California/7/2009 NYMC X-179A)
9 mcg
Suspension for injection
Active: Influenza virus A/California/7/2009 (H1N1) - like strain 9ug (A/California/7/2009 NYMC X-179A) Influenza virus A/Texas/50/2012 (H3N2) like strain 9ug (A/Texas/50/2012 NYMC X-223A) Influenza virus B/Massachusetts/2/2012 like strain 9ug (wild type) Excipient: Dibasic sodium phosphate dihydrate Hydrochloric acid Monobasic potassium phosphate Potassium chloride Sodium chloride Sodium hydroxide Water for injection
Syringe, glass, 0.1mL, 1 dose unit
Prescription
Prescription
Sanofi Pasteur SA
INTANZA 9mcg is indicated for prophylaxis of influenza in adults from 18 to 59 years of age. The use of INTANZA 9mcg in New Zealand should be based on the Ministry of Health recommendations for influenza vaccination as published in the current New Zealand Immunisation Handbook.
Package - Contents - Shelf Life: Syringe, glass, 0.1mL - 1 dose units - 12 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Syringe, glass, 0.1mL - 10 dose units - 12 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light
2009-07-07
NEW ZEALAND CONSUMER MEDICINE INFORMATION INTANZA ® , 9μg/strain/0.1ml, suspension for injection in pre-filled syringe with a Micro-Injection system Influenza Vaccine (split virion, inactivated) WHAT IS IN THIS LEAFLET READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE VACCINATED. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This vaccine has been prescribed for you. Do not pass it on to others. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: What INTANZA 9ΜG is and what it is used for Before you use INTANZA 9ΜG How to use INTANZA 9ΜG Possible side effects Storing INTANZA 9ΜG Further information WHAT INTANZA 9ΜG IS AND WHAT IT IS USED FOR INTANZA 9ΜG is a vaccine. Vaccines are used to protect you against infectious diseases. This vaccine is recommended to help to protect you against influenza. The vaccine may be administered to persons 18 to 59 years of age, especially in those who run an increased risk of associated complications. When an injection of INTANZA 9ΜG is given, the immune system (body's natural defences) will induce protection against Influenza infection. INTANZA 9ΜG will protect you against Influenza infection from about 2 to 3 weeks after the injection. Page 1 of 6 Influenza is a disease caused by different types of virus and can spread rapidly, especially in homes or institutions where it is very easy to catch and spread the infection. The greatest risk of catching influenza is during the cold months between May and October. Your doctor will be able to recommend you the best time to be vaccinated. Influenza is present every year even when epidemics or outbreaks are not reported. INTANZA 9ΜG should be used in accordance with official recommendations for influenza vaccination. Прочетете целия документ
INTANZA Intradermal 9μg Dose Influenza Vaccine for persons 18-59 years of age 2013 season Page 1 of 10 DATA SHEET NAME OF THE MEDICINE INTANZA 9μg/strain/0.1 mL suspension for injection in pre-filled syringe with a Micro-Injection System. Influenza vaccine (split virion, inactivated). DESCRIPTION ACTIVE INGREDIENTS: Split Influenza virus*, inactivated, containing antigens equivalent to the following strains: A/CALIFORNIA/7/2009 (H1N1)PDM09-LIKE STRAIN (A/CALIFORNIA/7/2009 NYMC X-179A) 9 MICROGRAMS HA** A/VICTORIA/361/2011 (H3N2)-LIKE STRAIN (A/VICTORIA/361/2011 IVR-165) 9 MICROGRAMS HA** B/ WISCONSIN/1/2010-LIKE STRAIN (B/HUBEI-WUJIAGANG/158/2009 NYMC BX-39) 9 MICROGRAMS HA** Per 0.1 mL dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** haemagglutinin The vaccine complies with the TGA recommendations (Southern Hemisphere) for the 2013 season. EXCIPIENTS: Buffer solution: • Sodium chloride • Potassium chloride • Sodium phosphate - dibasic dihydrate • Potassium phosphate - monobasic • Water for injections No adjuvant or antimicrobial preservative is added. The vaccine does not contain more than 0.05 microgram of ovalbumin per dose. In each dose the vaccine may contain traces of octoxinol 9 (≤ 150 microgram), formaldehyde (≤ 0.6 microgram) and neomycin (≤ 0.05 picogram). The vaccine is a colourless and opalescent suspension for injection in pre-filled syringe with a Micro-Injection System. INTANZA Intradermal 9μg Dose Influenza Vaccine for persons 18-59 years of age 2013 season Прочетете целия документ